descr

PaxVax Inks Swiss Marketing and Distribution Agreement with Seqirus for Influenza Vaccines

REDWOOD CITY, California, USA – August 29, 2016 – PaxVax, a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that the company has entered into a marketing and distribution agreement with Seqirus. Under the terms of this agreement, PaxVax will market, sell and distribute two of Seqirus’ influenza vaccine products in Switzerland, Agrippal® (surface antigen, inactivated) and Fluad™ (influenza vaccine, adjuvanted). 

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS